Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $322.6 million.

  • Akebia Therapeutics' Total Liabilities rose 2524.46% to $322.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $322.6 million, marking a year-over-year increase of 2524.46%. This contributed to the annual value of $269.9 million for FY2024, which is 89.32% down from last year.
  • Per Akebia Therapeutics' latest filing, its Total Liabilities stood at $322.6 million for Q3 2025, which was up 2524.46% from $316.4 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Total Liabilities high stood at $519.2 million for Q1 2022, and its period low was $252.7 million during Q1 2024.
  • Its 5-year average for Total Liabilities is $349.2 million, with a median of $316.4 million in 2025.
  • As far as peak fluctuations go, Akebia Therapeutics' Total Liabilities soared by 2985.53% in 2021, and later tumbled by 4221.13% in 2023.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Total Liabilities stood at $455.3 million in 2021, then decreased by 22.95% to $350.8 million in 2022, then decreased by 22.39% to $272.3 million in 2023, then fell by 0.89% to $269.9 million in 2024, then grew by 19.53% to $322.6 million in 2025.
  • Its Total Liabilities stands at $322.6 million for Q3 2025, versus $316.4 million for Q2 2025 and $285.6 million for Q1 2025.